Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetuximab + QTX3034 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
QTX3034 | QTX-3034|QTX 3034 | KRAS Inhibitor 18 | QTX3034 is a selective allosteric inhibitor of KRAS, which potentially decreases tumor cell proliferation and inhibits tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): LB_C09, Cancer Res (2023) 83 (8_Supplement): LB320). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06227377 | Phase I | QTX3034 Cetuximab + QTX3034 | QTX3034 in Patients With KRAS G12D Mutation | Recruiting | USA | 0 |